

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT IS NOT AN OFFER FOR SALE OR SUBSCRIPTION IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION. THIS ANNOUNCEMENT IS NOT AN OFFER OF OR SOLICITATION TO PURCHASE OR SUBSCRIBE FOR SECURITIES IN THE UNITED STATES.

23 July 2024

Arecor Therapeutics plc
("Arecor Therapeutics" or the "Company")

Posting of Circular and Notice of General Meeting

Arecor Therapeutics (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, is pleased to announce that further to the announcement on 19 July 2024 confirming the results of the Placing and Subscription, and the announcement earlier today confirming the results of the Retail Offer, it is today posting to Shareholders the Circular including a notice convening the General Meeting in respect of the conditional Fundraising.

The General Meeting will be held at the offices of Covington & Burling LLP at 22 Bishopsgate, London EC2N 4BQ at 1:00 p.m. on 8 August 2024.

The Circular will shortly be available on the Company's website: www.arecor.com

Capitalised terms used in this announcement have the meanings given to them as ascribed in the Company's announcement released at 1:10 p.m. on 19 July 2024.

For further information, please contact:

Arecor Therapeutics plc www.arecor.com
Sarah Howell, Ph.D, Chief Executive Officer
Tel: +44 (0) 1223 426060
Email: info@arecor.com

Panmure Liberum Limited (NOMAD, Joint Bookrunner and Joint Broker) Tel: +44 (0) 20 7886 2500
Emma Earl, Freddy Crossley, Mark Rogers (Corporate Finance)
Rupert Dearden (Corporate Broking)

WG Partners LLP (Joint Bookrunner and Joint Broker) Tel: +44 (0) 20 3705 9321
Nigel Barnes, Satheesh Nadarajah
David Wilson, Claes Spang

Beech Hill Securities, Inc. (Placement Agent) Tel: +1 212 350 7200
George Billington, Thomas Lawrence

ICR Consilium Tel: +44 (0) 20 3709 5700
Chris Gardner, David Daley, Lindsey Neville
Email: arecor@consilium-comms.com

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

IMPORTANT NOTICES

This Announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the Securities Act, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.

This Announcement does not constitute an offer to sell, or the solicitation of an offer to acquire or subscribe for, Ordinary Shares in any jurisdiction where such offer or solicitation is unlawful or would impose any unfulfilled registration, qualification, publication or approval requirements on the Company. The offer and sale of Ordinary Shares has not been and will not be registered under the applicable securities laws of Australia, Canada, the Republic of South Africa or Japan. Subject to certain exemptions, the Ordinary Shares may not be offered to or sold within Australia, Canada, the Republic of South Africa or Japan or to any national, resident or citizen of Australia, Canada, the Republic of South Africa or Japan.

This Announcement does not constitute, or form part of, any offer or any solicitation of an offer to subscribe for any shares or other securities, nor shall it (or any part of it) or the fact of its dissemination form the basis of, or be relied on in connection with, any contract with respect thereto.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CIRPPUWPMUPCGAW